However, head-to-head studies of tau-PET radioligands are needed to clarify this issue as these minor regional discrepancies could also be due to population differences: the TRIAD cohort includes more early onset AD subjects, who have greater cortical tau pathology compared with late onset AD subjects [49]. The gene discussed is MAPT; the disease is Alzheimer disease.